Dr. Sideras is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4500 San Pablo Rd S
Jacksonville, FL 32224Phone+1 904-953-2000
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2005 - 2009
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2002 - 2005
- Stony Brook University Health Sciences Center School of MedicineClass of 2002
Certifications & Licensure
- FL State Medical License 2019 - 2025
- MN State Medical License 2019 - 2025
- SC State Medical License 2024 - 2025
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer Start of enrollment: 2010 May 01
Publications & Presentations
PubMed
- 275 citationsTestosterone and Cardiovascular Risk in Men: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled TrialsRudy M. Haddad, Cassie C. Kennedy, Sean M. Caples, Michal J. Tracz, Enrique R. Boloña
Mayo Clinic Proceedings. 2007-01-01 - 113 citationsPD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma.Kostandinos Sideras, Katharina Biermann, Joanne Verheij, B. Takkenberg, Shanta Mancham
Oncoimmunology. 2017-01-03 - 317 citationsEfficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.Keith C. Bible, Vera J. Suman, Julian R. Molina, Robert C. Smallridge, William J. Maples
The Lancet. Oncology. 2010-10-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: